Immunocore Holdings plc — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Immunocore announced full enrollment of 540 patients in TEBE-AM, a Phase 3 registrational trial testing KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab versus Investigator's Choice in HLA-A*02:01-positive patients with previously treated advanced melanoma. The primary endpoint is overall survival; topline data expected end of 2026. The trial addresses an estimated 4,000-patient addressable market in the US and Europe for the post-PD1 setting.
Why this rating
Enrollment completion is a key de-risking milestone for lead late-stage program. Material for $1.5B biotech: successful Phase 3 enrollment removes execution risk, supports potential accelerated approval path, de-risks revenue runway. Results still pending.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.